We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+10.35%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$346M
AUM Growth
-$33M
Cap. Flow
-$24.2M
Cap. Flow %
-6.99%
Top 10 Hldgs %
58.05%
Holding
59
New
16
Increased
15
Reduced
9
Closed
13

Top Buys

1
SRPT icon
Sarepta Therapeutics
SRPT
+$9.88M
2
ASND icon
Ascendis Pharma A/S
ASND
+$9.34M
3
FOLD
Amicus Therapeutics
FOLD
+$8.74M
4
MRSN
Mersana Therapeutics
MRSN
+$8.59M
5
VRNA
Verona Pharma
VRNA
+$5.57M

Top Sells

1
IMMU
Immunomedics Inc
IMMU
+$20.4M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$13M
3
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$12.8M
4
TGTX icon
TG Therapeutics
TGTX
+$9.2M
5
AXSM icon
Axsome Therapeutics
AXSM
+$8.23M

Sector Composition

1 Healthcare 77.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$50.3M 14.53%
451,000
+151,000
+50% +$16.9M
TRIL
2
DELISTED
Trillium Therapeutics Inc.
TRIL
$27.7M 8.01%
1,950,000
+425,000
+28% +$4.24M
ASND icon
3
Ascendis Pharma A/S
ASND
$17.1B
$20.1M 5.8%
130,000
+65,000
+100% +$9.34M
MRSN
4
DELISTED
Mersana Therapeutics
MRSN
$19.6M 5.65%
42,000
+17,000
+68% +$8.59M
IOVA icon
5
Iovance Biotherapeutics
IOVA
$2.23B
$18.9M 5.47%
575,000
-5,000
-0.9% -$153K
IMVT icon
6
Immunovant
IMVT
$8.27B
$18.5M 5.34%
525,000
– –
CNST
7
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$14.7M 4.25%
725,000
+75,000
+12% +$1.83M
ADVM
8
DELISTED
Adverum Biotechnologies
ADVM
$12M 3.46%
116,138
+26,138
+29% +$3.91M
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.96M 2.88%
60,000
-95,000
-61% -$13M
ALDX icon
10
Aldeyra Therapeutics
ALDX
$102M
$9.26M 2.68%
1,250,000
+250,000
+25% +$1.61M
RCKT icon
11
Rocket Pharmaceuticals
RCKT
$376M
$9.14M 2.64%
400,000
-250,000
-38% -$6.16M
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.82B
$9.13M 2.64%
+65,000
New +$9.88M
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
$8.47M 2.45%
+600,000
New +$8.74M
AUPH icon
14
Aurinia Pharmaceuticals
AUPH
$2.05B
$8.1M 2.34%
550,000
– –
FATE icon
15
Fate Therapeutics
FATE
$324M
$7.99M 2.31%
200,000
+75,000
+60% +$2.62M
SURF
16
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$6.9M 1.99%
1,000,000
+300,000
+43% +$1.82M
KURA icon
17
Kura Oncology
KURA
$964M
$6.89M 1.99%
+225,000
New +$4.97M
BCRX icon
18
BioCryst Pharmaceuticals
BCRX
$2.36B
$6.7M 1.94%
1,950,000
+50,000
+3% +$214K
SNDX icon
19
Syndax Pharmaceuticals
SNDX
$2.02B
$6.27M 1.81%
425,000
+240,000
+130% +$3.66M
AGIO icon
20
Agios Pharmaceuticals
AGIO
$2.36B
$6.13M 1.77%
175,000
+60,000
+52% +$2.63M
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.64M 1.63%
1,000,000
+100,000
+11% +$477K
TGTX icon
22
TG Therapeutics
TGTX
$8.4B
$5.35M 1.55%
200,000
-400,000
-67% -$9.2M
VRNA
23
DELISTED
Verona Pharma
VRNA
$5.03M 1.45%
+805,556
New +$5.57M
IMUX icon
24
Immunic
IMUX
$207M
$4.92M 1.42%
+26,500
New +$4.34M
ARVN icon
25
Arvinas
ARVN
$517M
$4.72M 1.36%
200,000
+80,000
+67% +$2.32M
1
2 3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Ghost Tree Capital held 59 positions worth $346M, down 8.7% from $379M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Ghost Tree Capital withdrew a net $24.2M in Q3 2020, closing 13 positions and reducing 9 holdings. Its most notable exit was Immunomedics Inc, an estimated $20.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 71% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Sarepta Therapeutics worth $9.13M.

  • Ghost Tree Capital's largest Q3 2020 buy was Sarepta Therapeutics: 65,000 shares worth $9.13M.
  • Ghost Tree Capital added most to Ascendis Pharma A/S in Q3 2020, an estimated $9.34M increase.
  • Ghost Tree Capital's biggest Q3 2020 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $13M.
  • Ghost Tree Capital fully exited Immunomedics Inc in Q3 2020, selling an estimated $20.4M.
  • Ghost Tree Capital's ten largest holdings make up 58% of its $346M portfolio in Q3 2020.
  • Ghost Tree Capital opened 16 new positions and closed 13 in Q3 2020.
  • Ghost Tree Capital's portfolio value fell 8.7% quarter-over-quarter to $346M.

Based on Ghost Tree Capital's 13F filing for Q3 2020, filed 16 Nov 2020.